Pfizer Inc (PFE): Revenue
$62.58B
Year ended 2025-12-31
$63.70B
Trailing 12 months to 2026-06-28
-14.8%
3-year compound annual growth
+8.5%
5-year compound annual growth
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $62.58B | -1.6% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $63.63B | +6.8% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $59.55B | -41.1% | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | $101.17B | +24.5% | 2025-02-27, From 2022-01-01 |
| 2021-12-31 | $81.29B | +95.2% | 2024-02-22, From 2021-01-01 |
| 2020-12-31 | $41.65B | +1.8% | 2023-02-23, From 2020-01-01 |
| 2019-12-31 | $40.91B | +0.2% | 2022-02-24, From 2019-01-01 |
| 2018-12-31 | $40.83B | n/c | 2021-02-25, From 2018-01-01 |
| 2017-12-31 | $52.55B | -0.5% | 2020-02-27, From 2017-01-01 |
| 2016-12-31 | $52.82B | n/a | 2019-02-28, From 2016-01-01 |
Revenue at similar companies
| Company | Year ended | Revenue | Change YoY |
|---|---|---|---|
| Pfizer Inc (PFE) | 2025-12-31 | $62.58B | -1.6% |
| AbbVie Inc. (ABBV) | 2025-12-31 | $61.16B | +8.6% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $65.01B | +1.3% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $65.18B | +44.7% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $48.19B | -0.2% |
| Abbott Laboratories (ABT) | 2025-12-31 | $44.33B | +5.7% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $94.19B | +6.0% |
| Teva Pharmaceutical Industries Ltd (TEVA) | 2025-12-31 | $17.26B | +4.3% |
| Regeneron Pharmaceuticals, Inc. (REGN) | 2025-12-31 | $14.34B | +1.0% |
Compare PFE, ABBV, MRK, LLY side by side · Screen every company in Pharmaceutical Preparations ↗